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Abstract 
Mitotic kinetochores are signaling network hubs that regulate chromosome movements, attachment 
error-correction, and the spindle assembly checkpoint. Key switches in these networks are kinases 
and phosphatases that enable rapid responses to changing conditions. Describing the mechanisms 
and dynamics of their localized activation and deactivation is therefore instrumental for 
understanding the spatio-temporal control of chromosome segregation. 
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1. Introduction 
Named by Lester Sharp in the early 1930’s for their apparent ability to power chromosome 
movements, kinetochores are the business ends of chromosomes during mitosis. They are large 
protein assemblies that connect chromatin to the mitotic spindle which is tasked with dragging 
identical, duplicated chromatids in opposite directions. Kinetochores are therefore the focal points 
of signaling networks that regulate chromosome-spindle attachments and cell cycle progression (1-
3) .  
 Prometaphase is the time of mitosis during which the chromosomes attempt to become 
bioriented, that is, to have each sister from a pair of duplicate chromosomes attach to microtubules 
from opposite spindle poles. In mammalian cells, this process is quite error-prone. In fact, many 
initial attachments are of the so-called syntelic kind and are in need of correcting (4-6). 
Consequently, error-correction mechanisms have evolved that enable iterative rounds of 
detachment-attachment until a chromosome is bioriented. All the while, anaphase initiation cannot 
be permitted. Surveillance of attachment/biorientation and transmission of that information to the 
cell cycle machinery is the primary job of the spindle assembly checkpoint (SAC). The combined 
actions of the error-correction and SAC machineries therefore prevent erroneous chromosome 
segregations (7, 8).  
 As with most signaling networks wired to achieve speed and responsiveness, kinases and 
phosphatases are at the heart of attachment error-correction and the SAC. The kinases Aurora B, 
MPS1, BUB1, PLK1, and CDK1, and the phosphatases PP1 and PP2A-B56 all have major contributions. 
Several excellent reviews have summarized our current understanding of their molecular workings, 
and we therefore refer the reader to those for detailed insights (1-8). For the purpose of this 
chapter, however, the following is relevant; localization of BUB1 to human kinetochores is crucial for 
SAC activity as it ensures localized production of the wait-anaphase signal. BUB1 recruitment is 
induced by MPS1, which phosphorylates multiple repeated motifs in the kinetochore scaffold KNL1 
to create phospho-docking sites for the BUB1 adaptor BUB3 (figure 1). The axis Aurora B - MPS1 - 
3 
 
BUB1 is not only at the heart of the SAC, it is also the core of attachment error-correction: Aurora B 
phosphorylates microtubule- binding proteins such as NDC80/HEC1 to allow destabilization of 
erroneous attachments (figure 1). MPS1 ensures localized Aurora B activity and likely has other 
targets required for efficient error-correction. Finally, BUB1 promotes Aurora B localization by 
phosphorylating histone H2A on T120. Therefore the error-correction and SAC pathways are 
extensively entwined, and this is further exemplified by the fact that the phosphatases PP1 and 
PP2A-B56 counteract both error-correction and the SAC to stabilize chromosome spindle 
attachments and allow anaphase onset (9-14).  
 Recent years have seen much advance in our mechanistic understanding of localized 
activation and inactivation of kinetochore kinase signaling pathways. This is largely due to reagents 
that allow immediate inhibition of kinases, and reagents to monitor kinase output at high spatial and 
temporal resolution. This chapter describes how reagents such as small molecule inhibitors and 
phospho-specific antibodies can be used to draw meaningful conclusions about kinetochore kinase 
function.  
 
2. Material 
 
2.1 Visualising and quantifying kinase localisation and activity – fixed analysis 
 
1. High precision 1.5H 12 mm coverslips. 
2. Poly-L-lysine solution (Sigma Aldrich). Dilute 1:10 in PBS (0.01% w/v) just prior to coating wells. 
3. Nocodazole (Millipore or Sigma Aldrich). Make 1 mg/ml stock in DMSO and store at -20°C. 
4. Paclitaxel (Taxol; LC Labs). Make 1 mM stock in DMSO and store at -20°C. 
5. Noscapine (Tocris Biosciences). Make 50 mM stock in ddH2O and store at -20°C. 
6. S-Trityl-L-cysteine (STLC; Sigma Aldrich). Make 10 mM stock in DMSO and store at -20°C. 
7. Monastrol (Tocris Biosciences). Make 200 mM stock in DMSO and store at -20°C. 
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8. MG-132 (Sigma Aldrich). Make 5 mM stock in DMSO and store at -20°C. 
9. Pro-TAME (Boston Biochem). Provided as a 20 mM stock in DMSO. 
10. Thymidine (Sigma Aldrich). Make 200 mM in H2O, store at room temperature and use within 2 
weeks (see note 1). 
11. Pre-extraction media (PEM). 100 mM PIPES (pH 6.8), 1 mM MgCl2, 5 mM EGTA, 0.2% Triton X-
100 (all Sigma Aldrich). Mix fresh immediately prior to use. 
12. Paraformaldehyde (Sigma Aldrich). Use the prilled version to prevent noxious powder from 
being released when weighing (see note 2). 
13. 245 mm square plates (Corning). For use as an antibody incubation chamber. 
14. Parafilm. 100 mm wide for antibody incubations. 
15. Various primary antibodies, listed in Table 1. 
16. Alexa Fluor® range of fluorescent secondary antibodies (Life Technologies). Use highly cross-
adsorbed versions wherever possible to limit cross-reaction. 
17. 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma Aldrich). Make 1 mg/ml stock in 
H2O and store at -20°C. Store working stock at 4°C for up to 3 months. 
18. Microscope slides (72 x 25 mm). 
19. ProLong® Gold antifade mounting media (Life Technologies). 
20. Deltavision Elite deconvolution microscope (Applied Precision) equipped with a 100 X 1.4 
numerical aperature (NA) objective and a Coolsnap HQ2 (Photometrics) CCD camera. Other 
similar automated microscope setups capable of multi-position imaging and high precision Z-
sectioning could perform equally well. 
21. Fiji ImageJ. Open source image analysis software (download from http://fiji.sc/Fiji). 
 
2.2 Visualising and quantifying kinase localisation – live imaging 
 
1. 8-well chamber -slide (Ibidi) 
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2. Syringe and 23G needle 
3. Leibovitz-15 (L-15) medium supplemented with 10% FBS and 1% PenStrep (all Life 
Technologies). 
     
2.3 Modulating kinetochore kinase activity 
 
A number of different kinase inhibitors have been developed to target kinetochore kinases. In 
addition, various gatekeeper kinase mutants have also been developed using the Shokat approach to 
achieve specific kinase inhibition (See Jallepalli et al in this volume)  (18). These are listed in Table 2. 
 
3. Methods – fixed cells analysis 
 
3.1 Determining the correct experimental conditions 
 
Kinetochore kinase activity is always affected (directly or indirectly) by kinetochore-microtubule 
attachment or tension. Therefore, as mitosis progresses the kinase activity at individual kinetochores 
will change as kinetochore-microtubule attachments form. For this reason, it is usually advisable to 
reduce this variability by performing experiments in the presence of nocodazole to inhibit 
microtubule polymerisation (see note 3). 
 
To measure the effects of microtubule attachment on kinetochore kinase activity directly, various 
inhibitors can be used to enrich cells at different stages of kinetochore-microtubule attachment (as 
outlined in table 3) 
 
If required, the total number of mitotic cells can be further enriched by thymidine synchronisation 
prior to inhibitor treatment (see note 5). 
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1. Arrest cells for 24 h in full growth media and thymidine (2 mM). 
2. Wash cells 1X in PBS and release into full growth media for 6 h 
3. Add fresh media containing required drugs (except for MG-132 which prevents mitotic entry 
and so must be added 8-12 h after the thymidine release) 
4. Cells will be enriched in mitosis after a total of 8-12 h following thymidine release 
(depending on cell type). 
 
3.2 Setting up a fixed-cell imaging experiment. 
 
1. Transfer coverslips to 24 well plates using a vacuum aspirator to transfer sterile coverslips 
inside a tissue culture hood. 
2. Plate cells onto coverslips at required density in 0.5 ml media and then immediately press 
coverslip down with a pipette tip to ensure no air is trapped beneath (see note 6).  
3. Allow at least 24 h for cells to attach, but often longer depending on experimental 
conditions (siRNA knockdown, synchronisation etc; see note 7). 
4. When the particular mitotic state is achieved, cells should be fixed, with or without prior 
pre-extraction with PEM to decrease the cytosolic signal (see note 8). 
5. If pre-extraction is required, remove media and add 0.5 ml PEM for 60 s before adding 0.5 
ml 4% PFA for an additional 2 min (see note 9). 
6. Remove media or PEM/PFA and add 4% PFA for 10 min (see note 10) 
7. Wash 3X in PBS. 
 
3.3 Staining with total and phospho-specific antibodies. 
 
1. Block coverslips in PBS + 3% BSA + 0.2% triton (0.5 ml/well) for at least 30 min. 
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2 Replace blocking solution with PBS. 
3 Dilute primary antibodies in PBS/3% BSA (see note 11) 
4 Add 40 l of primary antibody mix per coverslip onto parafilm (see note 12). Place coverslip 
on top (cells facing down) and leave at least 2 h at room temperature, but generally 
overnight at 4°C. 
5 Transfer coverslips back into the 24 well plate (cells facing upwards) and wash 3X in PBS for 
10 min each on a shaking platform. 
6 Dilute secondary antibodies (1:1000 of the Alexa Fluor® from Life Technologies) and DAPI 
(1:1000 of 1 mg/ml stock) in PBS + 3% BSA. Place coverslip on 40 l, exactly as for the 
primary incubation, but just leave at least 2 h at room temperature in the dark (see note 13). 
The kinetochore markers are usually stained with Alexa Fluor® 647, which allows the test 
proteins to be stained with the visible wavelengths. 
7 Transfer back into 24 well plate (cells facing upwards) and wash 3X in PBS for 10 min each. 
8 Dip coverslips in absolute ethanol and place cells face up on tissue paper to dry (for about 5 
min). 
9 Mount coverslips on slide in a small drop of ProLong® Gold antifade (Life Technologies) and 
leave overnight to set. 
 
3.3 Imaging 
 
1. The experiments were performed on a Deltavision Elite deconvolution microscope described 
in materials (Applied Precision). Other microscopes equipped with a motorised XY-stage and 
an accurate Z-stage motor may perform equally well. 
2. For each particular stain, allow enough time to image the full set of treatment groups with 
the same settings on the same day. This will ensure intensity variations are not artificially 
induced during sampling. 
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3. Start with the coverslip that is predicted to have the maximal signal intensity (this is often 
the control sample). 
4. Store the XY positions of 10-20 mitotic cells by visualising the DAPI signal through the 
eyepiece (see note 14). 
5. Switch the light path to the camera and change exposure settings for each channel to give a 
maximal kinetochore signal intensity of 1000-1500 (see note 15). 
6. Switch to the far-red channel to visualise the Alexa Fluor® 647 kinetochore signal (either ACA 
or Cenp-C). Move to position 1 and use the software to adjust the Z position to just below 
the lowest kinetochore and update the position. 
7. Repeat for each stored XY position without changing the manual focus on the microscope 
body. 
8. To simplify quantification choose the channels to be scanned in the same order every time. 
Our macros (see 3.4) are predesigned for the order: DAPI, test antibodies (488 and/or 568), 
kinetochore marker (647). 
9. Take 43 x 0.2 M sections upwards (from the stored z-position) for each XY position. Choose 
the option in Softworx to automatically deconvolve images and make maximum intensity 
projections of the deconvolved stacks. 
 
3.4 Quantifying kinetochore intensities 
 
Kinetochore intensities can be quantified in fiji imageJ by using a macro to automate the steps 
highlighted below. The aim is to quantify the kinetochore intensities with the test antibody as a ratio 
of the kinetochore marker intensity (after correcting each channel for background signal). Contact 
either the Saurin or Kops labs for macros predesigned for this purpose (as used in (16)).  
 
1. Open the deconvolved maximum intensity projection using fiji imageJ (see note 16). 
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2. Use crop to remove any non-mitotic cells in view. 
3. Create a selection of the DAPI signal using the “auto-threshold” command followed by 
“create selection”. Use “add to manager” to save this selection. 
4. Use “duplicate” to open the image again in a new image window. 
5. Move to the last channel in the new window, use the “convolve” filter to clearly define the 
kinetochores and create a selection of these kinetochores using the auto-threshold 
command, as previously. Enlarge the selection by 2 pixels (see note 17) and “add to 
manager”. This is the kinetochore region [KT]. 
6. Use the “make inverse” command to choose a selection outside of all kinetochores and 
“combine” with the DAPI selection to define a region outside of the kinetochores but inside 
the DAPI. This chromatin area can be used as the background region [BG] for most 
kinetochore kinases and substrates (see note 18). 
7. Close the duplicated window. 
8. In the original image window, measure the mean [KT] and [BG] intensity for all channels. 
9. Calculate KT intensities for the test antibody using the formula: [KT-BG]test antibody / [KT-
BG]kinetochore marker (see note 19). 
10. The change in KT intensity upon treatment can be calculated by: Mean KT intensity 
(control)/Mean KT intensity (treatment group) (see note 20). 
11. The mean and standard deviation of this ratio can then be calculated between individual 
experiments for statistical purposes. 
 
 
4. Methods – live cell imaging 
 
4.1 Setting up a live-cell imaging experiment.  
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1. Plate cells into 8-well chamber slides (Ibidi) using 250 l of media per well. Plate the same 
number of cells as for a standard well of a 24 well plate. 
2. On the day of the experiment, exchange media to L-15 (Leibovitz) media with serum for at 
least 3 h prior to imaging (mitotic entry is inhibited for the first few hours after switching to 
L-15; see note 21). 
3. Turn on the microscope heating unit to equilibrate the microscope to 37°C for at least 2 h 
prior to filming (see note 22). 
4. Secure the chamber slide into position in the stage holder and allow to equilibrate to 
temperature (see note 23). 
5. Determine the required exposure time and, if possible, try to minimise toxicity by sacrificing 
resolution using binning (see note 24). 
6. Run a test on a sample field of view to determine whether the chosen settings are suitable 
and that the level of bleaching is acceptable (see note 25). 
7. Start experiment and check again after a few time points to ensure there has been no focal 
drift (see note 26). 
 
4.2 Adding small molecules during time-lapse imaging. 
 
Adding and washing out drugs is possible during a time-lapse imaging experiment, but care must be 
taken not to move the chamber slide or dislodge the loosely attached mitotic cells. Also, if drugs are 
to be added to different wells from the start of a timelapse movie using the ibidi chamber slides, 
then this should be performed when the slide is positioned securely on the microscope and not in 
the tissue culture hoods (see note 27). 
 
1. Make sure the chamber slide is securely placed in position by ensuring the spring loaded 
slide holder is under sufficient tension (see note 28). 
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2. Remove the tight fitting lid from the chamber slide and place upside down to allow easy 
removal with minimum disturbance during filming. 
3. Start movie for the desired number of timepoints prior to drug addition and then pause. 
4. To remove media use a 5 ml syringe coupled to a 23G needle to withdraw media from the 
far corner of the well (as far away from the filming position as possible; see note 29). 
5. Add 250 l media containing drugs gently down the same corner of the well using a 1 ml 
pipette. 
6. Replace lid and continue filming (see note 30). 
 
 
5. Notes 
 
1 Check before use and if crystals have formed then make fresh. Store in a warm place to 
prevent crystallization. 
2 Dissolve at 4% in PBS by incubating for approximately 2 h at 60°C with occasional stirring. Do 
not to heat above 60°C since paraformaldehyde will degrade at high temperatures. Store at 
4°C and use within 2 days. Always warm to room temperature prior to use. 
3 This is particularly important if the chosen treatments are known to affect 
kinetochore/microtubule attachments, since these would otherwise indirectly affect kinase 
activity.  
4 Keep time of drug addition short because extended metaphase durations can lead to 
premature sister chromatid splitting due to cohesion fatigue (38, 39) 
5 This type of enrichment will induce variability in the length of time individual cells have spent 
in mitosis, which can indirectly impact on phosphorylation levels of some substrates (12). To 
reduce variability, treat with inhibitors for a fixed duration in non-synchronised cells.  
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6 If cells adhere poorly to glass then coat coverslips in poly-L-lysine solution for at least 1 h 
prior to addition of cells (remove and wash 3x in PBS just before cells are added). 
7 If experimental conditions are likely to alter the duration of mitosis then this could also 
indirectly affect substrate phosphorylation (see note 5). If required, treat with the Cdk1 
inhibitor RO-3306 (10 M) for 2 h (to induce mitotic exit and prevent new mitotic entry). 
Wash cells 3X in PBS and replace with fresh media (-/+ inhibitors, if required) for a fixed 
duration to standardise the length of time in mitosis (allow at least 15 min for mitotic entry 
following RO-3306 washout). 
8 For kinases or substrates that give a cytoplasmic signal, visualisation of the kinetochore signal 
can be improved by pre-extraction for 1 min in a triton-containing buffer (PEM) to 
permeabilise the membrane and remove cytosolic proteins. 
9 Take care not to dislodge mitotic cells, which are very loosely attached in the triton-
containing PEM buffer. The addition of PFA before the PEM is removed is important to 
prevent inadvertent loss of cells. 
10 For most antigens we find standard PFA fixation is sufficient, but a small number may benefit 
from alternative fixation methods. If the signal intensity is low, then try fixation in either 
methanol or methanol-acetone (50/50) at -20°C for 5 min. This fixes cells by protein 
denaturation which may reveal antibody epitopes that are otherwise obscured. 
11 A typical experiment will contain a kinetochore marker (human-ACA or Guinea Pig Cenp-C; 
both give strong signals and allow co-staining with mouse and/or rabbit antibodies) and a 
total kinase and/or phospho-substrate antibody (see table.1). For phospho-specific 
antibodies incubate with dephospho-peptide whenever possible, since we find this increases 
the phospho-specific signal even for antibodies that have been purified by phospho-peptide 
enrichment. 
12 Use a corning 245 mm square tissue culture plate for antibody incubations. Place a strip of 
parafilm (100 mm thickness) across the plate and draw a grid to represent a 24 well plate. 
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Place antibody drops directly onto the parafilm and perform coverslip incubations with the lid 
on to prevent evaporation. 
13 We use the highly cross-adsorbed options (goat anti-guinea pig for Cenp-C or goat anti-
human for ACA) because these show no cross-reaction with mouse/rabbit. If using sheep 
primary antibodies then use secondary antibodies raised in donkey, because we see 
significant cross-reaction with secondaries raised in goat. 
14 Choose cells that are separated from the surrounding cells to simplify the quantification. 
15 This allows for a 3-fold increase in signal before the 12-bit Coolsnap-HQ2 camera is 
overexposed. If this is set on the treatment group with the highest predicted kinetochore 
intensity this is usually sufficient to account for inter-cell variability and prevent 
overexposure (unless variability is particularly high, for example following transient protein 
overexpression). 
16 We routinely use maximum intensity projections, but it is also possible to use sum intensity 
projections to include all data from every Z-projection. This may be especially important if 
kinetochore volume changes occur between samples/treatments. Note that cytoplasmic 
background could then begin to obscure KT signals, if this is the case, then this can be 
reduced by removing sections above/below the kinetochores prior to projection. 
17 This selection should now encompass the kinetochore signal in the test antibody channel, but 
if the test sample is larger (as with Aurora B for example, which gives a diffuse signal around 
the kinetochore) then increase this number, as required. 
18 If the kinase or substrate localises to chromatin (e.g Aurora B, pH2A etc.) then choose a ring 
around the DAPI selection (i.e. cytoplasm) as the background region instead. 
19 Expressing the intensities as a ratio of an internal kinetochore control allows normalisation 
against changes in kinetochore size and/or antibody signal intensity, both of which can vary 
between cells and between experiments. 
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20 Expressing data as a fold-change following treatment normalises against variation in the 
relative signal intensity of target vs kinetochore marker, which can otherwise vary 
considerably between experiments.  
21 L-15 (Leibovitz) is a CO2-independent media, but standard media (minus phenol red to 
prevent autofluorescence) can be used if a 95% air/5% CO2 line is available at the microscope. 
22 If a large number of live microscopy experiments are performed then keep the microscope 
unit at 37°C permanently. This will prevent downtime without affecting the quality of the 
fixed analysis. 
23 Temperature fluctuations will cause the focal point to drift, therefore allow enough time for 
the temperature to stabilise and check the focus is steady for at least 5-10 mins before 
filming. 
24 By using 2x2 binning the resolution is decreased 4-fold with a corresponding 4-fold increase 
in fluorescence signal. 4x4 binding leads to 16-fold changes, which can be very important to 
increase low signal intensities if detailed resolution is not required. 
25 For example, if running a time series of 100 time points with 3 x Z sections every 5 min, then 
quickly image one area of cells with those settings (but without the time series delay). Use 
the data inspector in Softworx to measure fluorescence decay throughout the course of the 
100 images and try to ensure this is no more than 10%.  
26 If focal drift has occurred, use the microscope focus dial to update the correct focus in one 
position. This should correct all the other positions since they are all relative.  
27 The ibidi chamber slides have a very low depth to the wells and we have frequently observed 
mixing between the wells during transport (i.e. from tissue culture room to the microscope). 
This can be minimised by using very low volumes of media (150 ml per 8 well chamber), 
however we have found the safest option is to only add drugs when the chamber slide is 
securely positioned on the microscope stage. 
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28 If using different stage inserts then we find that blu-tack (or a similar flexible adhesive) is 
excellent for preventing movement during filming. 
29 Cut off the end of the needle to remove the bevelled edge and bend slightly. This will allow 
full removal of media when placing the needle into the corner of the well so that it just 
touches the base of the well. 
30 If washout is required, replace lid upside down and repeat same procedure at the time of 
drug washout. 
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Figure legends 
Figure 1. Network model of kinase/phosphatase signaling at kinetochores. A selected set of 
kinases and phosphatases that control error-correction and the SAC are indicated along with 
some of their relevant substrates. Solid lines indicate direct connections, dashed lines indicate 
indirect ones. 
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Figure 1: Network model of kinase/phosphatase signaling at kinetochores. A
selected set of kinases and phosphatases that control error-correction and the
SAC are indicated along with some of their relevant substrates. Solid lines indicate
direct connections, while dashed lines indicate indirect ones
Type Antibody Species Dilution Company Cat number 
/reference 
Kinase Aurora B 
(AIM-1, Clone 6) 
Mouse 1:1000 BD 
Transduction 
611083 
Kinase Bub1 Rabbit 1:1000 Bethyl A300-373A-1 
Kinase Cyclin B1 
(Clone GNS1) 
Mouse 1:500 Santa Cruz sc-245 
Kinase Cyclin B1 Rabbit 1:500 Santa Cruz sc-752 
Kinase MPS1, NT 
(Clone 3-472-1) 
Mouse 1:1000 Millipore 05-682 
Kinase Plk1 Rabbit 1:1000 Custom (15) 
Aurora B 
autophosphorylation 
site 
p-Aurora B 
(Thr232) 
Rabbit 1:4000 Rockland 600-401-677 
Aurora B chromatin 
substrate 
p-Histone H3 
(Ser10) 
Rabbit 1:10000 Millipore 06-570 
Aurora B inner 
kinetochore 
substrate 
p-CenpA 
(Ser7) 
Rabbit 1:1000 Millipore 07-232 
Aurora B outer 
kinetochore 
substrate 
p-NDC80 
(Ser55) 
Rabbit 1:1000 Genetex GTX70017 
BUB1 substrate p-Histone H2A 
(Thr120) 
Rabbit 1:4000 Active motif 39391 
CDK1 kinetochore 
substrate 
p-BUBR1 
(Ser670) 
Rabbit 1:2000 Custom (12) 
MPS1 
autophosphorylation 
site 
p-MPS1 
(Thr676) 
Rabbit 1:1000 Custom (16) 
MPS1 kinetochore 
substrate 
pMELT-KNL1 
(pThr943/Thr1155) 
Rabbit 1:2000 Custom (12) 
MPS1 kinetochore 
substrate 
pMELT-KNL1 
(pThr875) 
Rabbit  Custom (14) 
(17) 
PLK1 substrate p-BUBR1 
(Thr680) 
Rabbit 1:1000 Custom (11) 
Unattached 
kinetochore marker 
Mad1 
(Clone BB3-8)) 
Mouse 1:1000 Millipore MABE867 
Kinetochore marker KNL1 Rabbit 1:1000 Abcam ab-70537 
Kinetochore marker NDC80 
(Clone 9G3) 
Mouse 1:5000 Abcam ab-3613 
Kinetochore marker ACA Human 1:2000 Fitzgerald 90c-CS1058 
Kinetochore marker CenpC Guinea 
pig 
1:5000 Caltag  
Medsystems 
PD030 
 
Table 1: A list of kinetochore antibodies that have been verified to work by 
immunofluorescence 
 Kinase Small molecule inhibitor IC50  [work] in HeLa ref 
Aurora B ZM447439 130 nM 2 µM (19) 
 Hesperadin ~250 nM 100 nM (20) 
 various others, in (pre)clinical trials (21) 
MPS1 Mps1-IN1 367 nM 10 µM (22) 
 Reversine 98.5 nM 1 µM (23) 
 AZ3146 35 nM 2 µM (24) 
 NMS-P715 65 nM 1 µM (25) 
 Various others, in (pre)clinical trials  
PLK1 BI2536 0.83 nM 100 nM (26) 
 TAL 19 nM 1 µM (27) 
 Various others, in (pre)clinical trials (21) 
BUB1 None    
CDK1 RO-3306 35 nM 10 µM (28) 
 Note that various other CDK inhibitors are available, 
including roscovitine, flavopiridol and olomoucine, but they 
generally inhibit a broader range of CDK enzymes. 
 
‘shokat’ alleles     
AurB-as 
(L154A;H250Y) 
NA-PP1 ND 2 µM (29) 
Mps1-as (M602G 
and M602A) 
23-dMB-PP1/3MB-PP1 ND 1/10 µM (30, 31) 
PLK1-as 3MB-PP1 ND 10 µM (32) 
BUB1: is natural 
gatekeeper 
mutant (G866)  
2OH-BNPP1 250 nM Only in vitro (33) 
CDK1-as 
(chicken, none 
reported in 
humans) 
1NM-PP1 ND 10 µM (34) 
 
Table 2: A list of inhibitors against different kinetochore kinases 
 Drug Working 
concentration 
(in HeLa cells) 
Effect Uses 
Nocodazole 3.3 M Unattached 
kinetochores 
To visualise unattached kinetochores and 
determine maximal kinase activity (35, 36) 
Taxol 1 M Few unattached 
kinetochores 
Generates a few Aurora-B dependent 
unattached kinetochores due to lack of 
tension (37) 
Nocodazole 
 
20-80 nM Partial chromosome 
alignment 
To visualise attached kinetochores under 
tension and unattached or unaligned 
kinetochores within the same cell. 
Noscapine 2-25 M Partial chromosome 
alignment 
To visualise attached kinetochore under 
tension and unattached or unaligned 
kinetochores within the same cell. 
STLC 10 M Monotelic 
attachments 
To visualise attached and unattached 
kinetochores within the same cell (using 
Mad1 to mark unattached kinetochores) 
Monastrol 200 M Monotelic 
attachments or 
merotelic 
attachments (after 
washout) 
To visualise attached and unattached 
kinetochores within the same cell (using 
Mad1 to mark unattached kinetochores). 
Monastrol washout leads to increased 
number of merotelic attachments (i.e. one 
kinetochore attached to both spindle 
poles). 
MG-132 5 M Complete 
chromosomal 
alignment 
To visualise attached kinetochores under 
tension (see note 4). 
Pro-TAME 12 M Complete 
chromosomal 
alignment 
To visualise attached kinetochores under 
tension without inhibiting proteasome 
activity (see note 4). 
 
Table 3: A list of Inhibitors that can be used to modulate kinetochore–microtubule attachment 
status 
